PubMed Health⌕ Search

Biomedical subjects

C M Barnett

Publications and source records attributed to C M Barnett.

3 recordsLinked to original sources

Evidence of thymic reconstitution after highly active antiretroviral therapy in HIV-1 infection.

OBJECTIVES: We aimed to provide evidence of thymic reconstitution after highly active antiretroviral therapy (HAART) in HIV-1 infected patients and to correlate this with the restoration of peripheral naïve T cells. METHODS: Positron emission tomography (PET) enables definitive evidence of thymic activity, indicating functional potential. In this case study, a single patient who initiated HAART demonstrated reconstitution of the naïve T-cell pool and underwent thymic PET scans at baseline and 2 and 6 months following initiation of therapy. Two patients who failed to demonstrate such reconstitution acted as controls. These patients (mean age 27 years) had chronic HIV infection with low CD4 T-cell counts (mean 82, range 9-160 cells/microL blood). Increased function of the thymus visualized by PET was correlated with phenotypic changes in CD4 and CD8 T cells in the periphery measured by flow cytometry, and with numbers of recent thymic emigrants measured by quantification of the numbers of T-cell receptor excision circles (TRECs) in peripheral cells. RESULTS: In one patient, clear correlations could be drawn between visible activity within the thymus, as measured by increased [F18]fluorodeoxyglucose (FDG) uptake, and regeneration of naïve CD4 (CD45RA/CD62L) T cells, increased numbers of CD4 T cells, controlled viraemia and increased numbers of recent thymic emigrants. A second patient displayed no increase in peripheral CD4 count and no increase in thymic activity. The third patient elected to stop therapy following the 2-month time point. CONCLUSIONS: The use of PET suggests that thymic activity may increase after HAART, indicating that the thymus has the potential to be functional even in HIV-1 infected persons with low CD4 T-cell counts.

Adult↗

A CT-based computerized treatment planning system for I-125 stereotactic brain implants.

A computer program has been developed at the University of California, San Francisco, as an aid in planning and evaluating stereotactic brain implants made with 125I seeds. The program allows images of seeds and catheters to be positioned in the target volume revealed by CT. It then generates and displays the resulting isodose distributions. Catheters may be changed interactively until an optimum implant is achieved. From the geometry of a stereotactic implant frame as measured by CT, the program calculates the approach angles of the catheters in the frame coordinate system. After the seeds are implanted, films made with a fiducial marker box can be used to generate true seed positions and hence true isodoses. This paper describes mathematically the geometrical transformations used by the program, and also outlines its many features and options. In its first 2 years of use the program has proved to be a valuable contributor to improved patient care.

Brachytherapy↗

Interstitial brachytherapy for metastatic brain tumors.

Since December 1979, 14 patients with progressive metastatic brain lesions have been treated with temporary implantation of high-activity iodine 125 sources using stereotaxic techniques. Four patients had prior surgical resections, and 13 had been treated with external whole-brain radiotherapy. Nine patients had brachytherapy performed at recurrence 4 to 16 months after conventional radiation therapy; the other four had implants as an adjuvant "boost" to the tumor area from 2 to 4 weeks after external radiation. Six patients have since died: two with stable brain lesions at 4 and 22 weeks, respectively; three with progressive systemic and CNS tumors at 23, 24, and 29 weeks, respectively; and one with progressive CNS disease 116 weeks postimplant. The remaining eight patients are alive with a median follow-up of 63 weeks (range, 52-239+ weeks). Median survival for the entire group is 80 weeks. Brain tumor brachytherapy may be useful for palliation and possible long-term survival in selected patients with solitary metastatic disease.

Adult↗